Ale's World of Stocks on $OBX (Nov 15, 2026)
Obsidian is a speculative early-stage investment, hard to evaluate, with potential for significant gains but significant risk if its flagship drug cannot reach the market; revenue is almost nil with losses in the hundreds of millions, while $350 million raised should fund it through 2027 trial results. The speaker does not own it and will follow it on a watchlist.
Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy
Jump to any passage
We begin with a small clinical-stage biotechnology company called Obsidian Therapeutics, ticker symbol OBX, which Google, according to documents, has added to its investment portfolio with an investment of approximately $16.8 million.
To clarify, this is not a sudden decision by Google to day-splurge on cheap biotech stocks. Obsidian went public in August through a reverse merger with a struggling biotech company called Galera Therapeutics, in which Google’s early investment arm had a private investment.
That company whose shares have now been converted to public shares.
But if we look at this stock chart, we will find that the company’s journey has been extremely rough since its IPO, with its stock value falling by more than 60%, bringing its market capitalization to less than $800 million, which is generally considered to be in the small business category.
But what exactly does this company do? Well, Obsidian is working on developing next-generation cell therapies to combat cancerous tumors such as advanced skin cancer and lung cancer.
These treatments involve taking immune cells from the patient's own tumor, engineering them in the laboratory, and then injecting them into the body to eliminate the cancer.
However, current cell therapies , such as these or similar ones, suffer from a major problem: they require high doses of toxic chemicals after treatment, unfortunately leading to nearly a quarter of patients being admitted to intensive care, and even carrying strong warnings.
But Obsidian's flagship drug, called Amso K cell, attempts to solve this problem by engineering cells with a built-in switch that doctors can control using a simple FDA-approved oral medication , which would, in theory, eliminate toxic side effects and allow patients to receive treatment on an outpatient basis.
In the second phase of their trials on skin cancer patients who had not responded to conventional treatments, 67% of them responded to the treatment with no associated deaths. For this reason, some Wall Street analysts see great potential for the company's stock to rise once this drug achieves significant success in the future.
However, the company's financial data is still very bad at the moment, with Obsidian generating almost no revenue , and analysts predicting only about $8 million by 2028, with losses still in the hundreds of millions of dollars in its attempt to get its flagship drug to market.
But the good news is that they recently raised $350 million in new funding, which will help them get through their important trial results in 2027. There is no doubt that the support of a giant company like Google, which has extensive experience in the field of biotechnology and strong relationships, will help them make further progress in the clinical phases.
As for me, I hope that any company that seeks to solve the biggest problems of cancer will succeed. But as an actual investment, it is difficult to evaluate them at this early stage, as I see it as more of a speculation, with the potential for significant future gains, but also involving significant risks if they cannot reach the market.
Therefore, it is a speculative investment by nature. I personally do not own shares in this company, but I am glad that Google’s support for it has made it a focus of my attention, and I will gladly add it to my watchlist and follow it closely in the future.
As for its ranking, I will temporarily place it in third place, until we see the other names on this list, then we can modify it later .